Search
Customer Support

Contact our support team if you have any enquiries about any of our products

Call: (856) 848-8698

Email: info@akersbio.com

Corporate Governance

We are committed to high standards of corporate governance, business integrity and professionalism in all our activities.

We have an audit committee, a compensation committee and a nominating and corporate governance committee. We have adopted a Code of Business Ethics and Conduct (the “Code of Ethics”) which constitutes a “code of ethics” as defined by applicable SEC rules and a “code of conduct” as defined by applicable NASDAQ rules. We require all employees, directors and officers, including our principal executive officer and principal financial officer to adhere to the Code of Ethics in addressing legal and ethical issues encountered in conducting their work. The Code of Ethics requires that these individuals avoid conflicts of interest, comply with all laws and other legal requirements, conduct business in an honest and ethical manner and otherwise act with integrity. The Code of Ethics contains additional provisions that apply specifically to our certain officers of the company and other finance department personnel with respect to accurate reporting.

Committee Composition

Company Ownership

Board of Directors

Thomas J. Knox, Ph.D. (HC), CLU, ChFC, FCPPNon-executive Chairman

Thomas Knox is a Philadelphia-based businessman who has owned, managed, and ultimately sold multiple profitable companies in the software, banking, and health insurance industries including Disc Systems, Inc., Crusader Bank, Gimco International, Kasser Industries and Fidelity Insurance Group. He also served as Chief Executive Officer for United HealthCare of Pennsylvania and served as Special Deputy Rehabilitator & Chief Executive Officer of Fidelity Mutual Life Insurance Co., Pennsylvania's 5th largest insurer. He was candidate for Mayor of Philadelphia in 2007 and candidate for Governor of Pennsylvania in 2010.

Raymond F. Akers Jr., Ph.D.Vice Chairman

Raymond Akers founded the company in 1989. He has vast experience in the diagnostics industry having co-founded Drug Screening Systems, Inc., a publicly listed company, in 1987 and Akers Medical Technology Inc., in 1984. He was President and Chief Executive Officer of Akers Medical Technology Inc. until 1987 and later Chief Executive Officer and Vice President of Research and Development of Drug Screening Systems, Inc. until the sale of that company in 1989. He holds a Ph.D. in Neurochemistry from Northwestern University. Dr. Akers is the inventor of the company’s platform technologies including Particle ImmunoFiltration Assay (PIFA), the basis for the company’s flagship rapid test for heparin induced thrombocytopenia (HIT).

Robert E. AndrewsNon-executive Director

Robert Andrews served as a Member of the U.S. House of Representatives from 1990 to 2014 as the Representative for New Jersey's 1st congressional district. During his time in the U.S. House of Representatives, he served on the Committee on Armed Services, Committee on the Budget, and Committee on Education and Labor, where he served as Chairman of the Subcommittee on Health, Employment, Labor, and Pensions. Robert was a candidate for the Democratic nomination in the 2008 U.S. Senate election. He retired from the House in 2014 to take the position of Counsel at Dilworth Paxson LLP where he also chairs the Government Affairs Group. He attended Cornell Law School, graduating magna cum laude in 1982.

Brandon KnoxNon-executive Director

Brandon Knox has been a wealth advisor at Raymond James in Philadelphia since 2012. His practice focuses on investment and estate solutions for high net worth families and individuals as well as public and private institutions both locally and nationally. Prior to joining Raymond James, Brandon was a wealth advisor at Morgan Stanley from 2008 to 2012. From 2006 to 2008, Brandon served as Deputy Finance Director for the Philadelphia mayoral campaign of his father, Thomas Knox. He also has experience in commercial real estate. Brandon holds a BS in Economics from West Chester University and an MBA in Financial Management from Drexel University.

Raza Bokhari M.D.Non-executive Director

Raza Bokhari has significant experience of working with life science and healthcare services companies. He is the Managing Partner of RBx Capital LP, a private equity fund focused on investing in the US laboratory testing market. Dr. Bokhari is also Chairman and CEO of Parkway Clinical Laboratories, a College of American Pathologists accredited national CLIA-certified clinical reference laboratory performing diagnostic testing procedures. Dr. Bokhari has a Doctor of Medicine degree from the University of Punjab, Rawalpindi Medical College, Pakistan, and an Executive MBA from The Fox School of Business at Temple University, PA, where he now serves as Chairman of the Executive Advisory Committee. Dr. Bokhari is frequently retained as a consultant for due diligence by private equity and venture capital funds focused on investing in life science, biotechnology and healthcare services companies.

Committee Composition

Name Audit Nominating and Governance Compensation
Thomas J. Knox, Ph.D. (HC), CLU, ChFC, FCPP Chair Member Member
Robert E. Andrews Member Member Chair
Brandon Knox Member Chair Member
Raza Bokhari M.D. Member Member Member

Chair = Chair Member = Member

Company Ownership

Shareholder Name Amount of Shares Owned % of Company
Chubeworkx Guernsey Limited 512,820 9.41%
ACT Capital Management, LLP 213,500 3.92%

There are currently 5,452,545 common shares in issue.

Insider Ownership

Director Name Amount % Holding
Thomas J. Knox, Ph.D. (HC), CLU, ChFC, FCPP 478,150 8.77%
Brandon Knox 124,326 2.28%
Robert E. Andrews 48,125 0.88%
Raza Bokhari M.D. 32,083 0.58%
Raymond Akers, Jr. PhD* 0 0.00%

* Dr. Akers does not directly own any shares in the Company, but is classified under AIM Rules as having a beneficial interest in a total of 72,100 shares by virtue of his wife being a trustee of the Akers Family Trust, which holds 70,000 shares, and as a result of her shareholding of 2,100 shares. These holdings represent an aggregate 1.32% of the total voting rights of the Company.